TABLE 2.
Main outcomes of the included studies.
| No | Study type | Study type | Sample | HPV ctDNA monitoring outcome |
|---|---|---|---|---|
| 1 | Leung et al. | Prospective clinical trial | Plasma | Detectable plasma HPV ctDNA at EOT timepoint was associated with shorter PFS |
| 2 | Jeannot et al. | Prospective cohort (the multicenter trial) | Serum | Significant association between HPV ctDNA at EOT and PFS was obtained |
| Baseline HPV ctDNA levels was not associated with PFS | ||||
| 3 | Cabel et al. | Prospective study | Serum/Plasma | HPV‐ctDNA detection at the end of CRT and/or during follow‐up was associated with shorter DFS |
| 4 | Lefèvre et al. | Prospective study | Plasma | High versus low median pretreatments plasma HPV levels had different DFS |
| 5 | Tanaka et al. | a Not specified | Plasma | No detectable ctHPV16DNA was associated with longer EFS |
| 6 | Chera et al. | Prospective biomarker clinical trial | Plasma | Actuarial 2‐year RFS rates between undetectable HPV ctDNA at all surveillance time points vs patients with at least one abnormal HPV ctDNA level were 30% for patients with an abnormal HPV ctDNA valus during post‐treatment surveillance and 100% for patients with negative HPV ctDNA value |
| 7 | Chera et al. | Prospective biomarker study | Plasma | Favorable clearance of ctHPV16DNA was associated with 100% RDFS |
| 8 | Bernard‐Tessier et al. | Multicenter prospective single‐arm trial | Serum | Detectable HPV ctDNA at the end of chemotherapy was associated with poorer PFS |
| 9 | Cabel et al. | Prospective study | Plasma/Serum | HPV ctDNA detection after CRT was strongly associated with shorter DFS |
| 10 | Dahlstrom et al. | Prospective cohort study | Plasma/serum | Negative and positive HPV ctDNA levels at the pretreatment timepoint were not significantly associated with longer PFS |
| 11 | Han et al. | Prospective multicenter study | Plasma | Patients with undetectable HPV ctDNA at CRT completion time had significantly longer PFS than those with detectable levels. |
| 12 | Routman et al. | Prospective study or part of clinical trials | Serum | Detectable HPV ctDNA level after surgical treatment was significantly associated with shorter RFS |
| 13 | Leung et al. | Not specified | Plasma | Patients with detectable HPV ctDNA at EOT timepoint had significantly shorter PFS compared to those with negative HPV ctDNA values |
a
The patients were newly diagnosed with HPV16‐related HNSCC and underwent radiotherapy with or without chemotherapy.